TrustCore Financial Services’s AbCellera Biologics ABCL Stock Holding History

TrustCore Financial Services’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$1.63K	Hold	161	–	–	﹤0.01%	915
2022 Q3	$2K	Hold	161	–	–	﹤0.01%	948
2022 Q2	$2K	Hold	161	–	–	﹤0.01%	929
2022 Q1	$2K	Hold	161	–	–	﹤0.01%	942
2021 Q4	$2K	Sell	161 -320	-67%	-$4.86K	﹤0.01%	864
2021 Q3	$10K	Hold	481	–	–	﹤0.01%	750
2021 Q2	$11K	Buy	481 +320	+199%	+$8.82K	﹤0.01%	710
2021 Q1	$5K	Hold	161	–	–	﹤0.01%	779
2020 Q4	$6K	Buy	+161	New	+$7.36K	﹤0.01%	740

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TrustCore Financial Services's ABCL Position: Q4 2022 in Review

TrustCore Financial Services held its AbCellera Biologics (ABCL) position steady in Q4 2022 at 161 shares worth $1.63K. The position accounts for ﹤0.01% of the portfolio, ranked #915.

TrustCore Financial Services first reported a position in ABCL in Q4 2020 and has held it in 9 quarters since. The position peaked at $11K in Q2 2021. 203 funds tracked by Wall St. Rank hold ABCL as of Q4 2022.

TrustCore Financial Services held 161 shares of AbCellera Biologics worth $1.63K as of Q4 2022.
TrustCore Financial Services left its AbCellera Biologics share count unchanged in Q4 2022.
AbCellera Biologics made up ﹤0.01% of TrustCore Financial Services's portfolio in Q4 2022, its #915 holding.
TrustCore Financial Services first reported a position in AbCellera Biologics in Q4 2020 and has held it in 9 quarters since.
TrustCore Financial Services's AbCellera Biologics position peaked at $11K in Q2 2021.
203 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2022.

Based on TrustCore Financial Services's 13F filing for Q4 2022, filed 13 Feb 2023.